Purdue Pharma, the embattled maker of the drug OxyContin, finds itself close to settling some of the thousands of lawsuits filed against it for the company's role in fueling the ongoing opioid epidemic.
The settlement forces the Sackler family to give up control of the Stamford, Connecticut-based business, according to the Associated Press, while the company will pay up to $12 billion over time.
Arizona Attorney General Mark Brnovic stated that the deal was the fastest way to help communities hit hard by the crisis while also increasing the payout initially offered by the defendant.
The pharmaceutical giant had been facing lawsuits from thousands of state, local, and Native American tribal governments. About 2,000 governments have agreed to the tentative deal, but about half of the states have not signed on.
"The families who were hurt by Purdue and the Sacklers have spoken loud and clear that this case demands real accountability, and I will continue to fight for that," Massachusetts Attorney General Maura Healey, who did not agree to the terms, wrote in a statement according to WBUR. “It’s critical that all the facts come out about what this company and its executives and directors did, that they apologize for the harm they caused, and that no one profits from breaking the law."
New Jersey Attorney General Gurbir Grewal also refrained from endorsing the settlement saying on Twitter, “New Jersey will continue to pursue all available legal options against those responsible. And if Purdue cannot pay for the harm it inflicted, the Sacklers will.”
The potential settlement comes two weeks after Johnson & Johnson was ordered to pay Oklahoma $572 million for its part in spreading addictive painkillers, a landmark first court decision during the opioid crisis that still fell short of the $17.2 billion the state was pursuing.
In March, Purdue and the Sacklers settled with the Sooner State for $272 million to pay for treatment, addiction research, and the state's legal fees.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
A look into how disruption, AI, and global economic trends are transforming the modern supply chain with Jeremy Jansen, Head of Supply Chain at Wells Fargo.
